Donahue KE, Jonas DE, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet]. AHRQ Publication No 12-EHCO25-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012. https://www​.ncbi.nlm​.nih.gov/pubmed/22696776. PMID: 22696776. [PubMed: 22696776]

Smolen JS, Collaud Basset S, Boers M, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016 Jul;75(7):1268–71. doi: 10.1136/annrheumdis-2016-209429. PMID: 27037326. [PMC free article: PMC4941171] [PubMed: 27037326] [CrossRef]

Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther. 2012 May 14;14(3):R112. doi: 10.1186/ar3838. PMID: 22584017. [PMC free article: PMC3446489] [PubMed: 22584017] [CrossRef]

de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013 Jan;72(1):72–8. doi: 10.1136/annrheumdis-2011-201162. PMID: 22679301. [PubMed: 22679301] [CrossRef]

Cummins L, Katikireddi VS, Shankaranarayana S, et al. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. Intern Med J. 2015 Dec;45(12):1266–73. doi: 10.1111/imj.12896. PMID: 26384029. [PubMed: 26384029] [CrossRef]

Todoerti M, Scirè C, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:139–45. doi: 10.1111/j.1749-6632.2009.05367.x. PMID: CN-00742547. [PubMed: 20398020] [CrossRef]

Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19–26. doi: 10.1136/annrheumdis-2014-206106. PMID: 25367713. [PMC free article: PMC4283672] [PubMed: 25367713] [CrossRef]

Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 Jul 16;388(10041):239–47. doi: 10.1016/s0140-6736(16)00380-9. PMID: 27197690. [PubMed: 27197690] [CrossRef]

Heimans L, Wevers-de Boer KV, Koudijs KK, et al. Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. Arthritis Res Ther. 2013 Oct 31;15(5):R173. doi: 10.1186/ar4361. PMID: 24517212. [PMC free article: PMC3978457] [PubMed: 24517212] [CrossRef]

van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet; 2009. p. 459–66. [PubMed: 19665644]

Bili A, Tang X, Pranesh S, et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Mar;66(3):355–63. doi: 10.1002/acr.22166. PMID: 24023053. [PubMed: 24023053] [CrossRef]

Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375–82. PMID: 18635256. [PubMed: 18635256]

Atsumi T, Yamamoto K, Takeuchi T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016 Jan;75(1):75–83. doi: 10.1136/annrheumdis-2015-207511. PMID: 26139005. [PMC free article: PMC4717398] [PubMed: 26139005] [CrossRef]

Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–93. PMID: 11096165. [PubMed: 11096165]

Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26–37. PMID: 16385520. [PubMed: 16385520]

Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum; 2008. p. 1467–74. [PubMed: 18821658]

St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004 Nov;50(11):3432–43. PMID: 15529377. [PubMed: 15529377]

Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum; 2007. p. 3919–27. [PubMed: 18050189]

Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Clin Rheumatol. 2010 Aug;29(8):913–20. doi: 10.1007/s10067-010-1425-3. PMID: 20496042. [PMC free article: PMC2895904] [PubMed: 20496042] [CrossRef]

Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 Sep;64(9):2824–35. doi: 10.1002/art.34498. PMID: 22508468. [PMC free article: PMC4036119] [PubMed: 22508468] [CrossRef]

Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58(4):220–5. [PMC free article: PMC1752864] [PubMed: 10364900]

Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353(9164):1568–73. [PubMed: 10334255]

Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36(10):1082–8. [PubMed: 9374925]

Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–18. PMID: 9251634. [PubMed: 9251634]

den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014 Jun;73(6):1071–8. doi: 10.1136/annrheumdis-2012-202818. PMID: 23606682. [PMC free article: PMC4033113] [PubMed: 23606682] [CrossRef]

Schipper LG, Fransen J, Barrera P, et al. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? Rheumatology (Oxford). 2009 Oct;48(10):1247–53. PMID: 19638454. [PubMed: 19638454]

Svensson B, Ahlmén M, Forslind K. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. In Clin Exp Rheumatol [PubMed: 12846051]

Lie E, Uhlig T, van der Heijde D, et al. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. Rheumatology (Oxford). 2012 Apr;51(4):670–8. doi: 10.1093/rheumatology/ker356. PMID: 22157597. [PubMed: 22157597] [CrossRef]

Conaghan PG, Østergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: Results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75(6):1024–33. doi: 10.1136/annrheumdis-2015-208267. [PMC free article: PMC4893111] [PubMed: 27002108] [CrossRef]

Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011 Jan;70(1):39–46. doi: 10.1136/ard.2010.137703. PMID: 20937671. [PubMed: 20937671] [CrossRef]

Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009 Dec;68(12):1870–7. PMID: 16935912. [PMC free article: PMC2770104] [PubMed: 19124524]

Burmester GR, Rigby WF, Van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–91. doi: 10.1136/annrheumdis-2015-207628. [PMC free article: PMC4893095] [PubMed: 26511996] [CrossRef]

Bijlsma JW, Welsing PM, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343–55. doi: 10.1016/s0140-6736(16)30363-4. PMID: 27287832. [PubMed: 27287832] [CrossRef]

Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013 Jun;72(6):844–50. doi: 10.1136/annrheumdis-2012-201612. PMID: 22739990. [PubMed: 22739990] [CrossRef]

Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014 Mar;73(3):536–43. doi: 10.1136/annrheumdis-2012-202433. PMID: 23316080. [PMC free article: PMC4151516] [PubMed: 23316080] [CrossRef]

Horslev-Petersen K, Hetland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014 Apr;73(4):654–61. doi: 10.1136/annrheumdis-2012-202735. PMID: 23434570. [PubMed: 23434570] [CrossRef]

Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013 Jan;72(1):64–71. doi: 10.1136/annrheumdis-2011-201247. PMID: 22562973. [PMC free article: PMC3551224] [PubMed: 22562973] [CrossRef]

Emery P, Bingham CO, 3rd, Burmester GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017 Jan;76(1):96–104. doi: 10.1136/annrheumdis-2015-209057. PMID: 27165179. [PMC free article: PMC5264210] [PubMed: 27165179] [CrossRef]

SA UP, Pharma U. A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis. https://ClinicalTrials.gov/show/NCT01519791; 2012.

Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis. 2013 Jun;72(6):851–7. doi: 10.1136/annrheumdis-2012-201365. PMID: 22753402. [PubMed: 22753402] [CrossRef]

Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Jan;52(1):27–35. PMID: 15641102. [PubMed: 15641102]

Singh JA, Saag KG, Bridges SL, Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1–25. doi: 10.1002/acr.22783. PMID: 26545825. [PubMed: 26545825] [CrossRef]

Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Mar 06. doi: 10.1136/annrheumdis-2016-210715. PMID: 28264816. [PubMed: 28264816] [CrossRef]

Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002 Apr;61(4):290–7. PMID: 11874828. [PMC free article: PMC1754044] [PubMed: 11874828]

Laires PA, Mesquita R, Veloso L, et al. Patient’s access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. BMC Musculoskelet Disord. 2013 Sep 25;14:279. doi: 10.1186/1471-2474-14-279. PMID: 24067096. [PMC free article: PMC3849024] [PubMed: 24067096] [CrossRef]

Meyfroidt S, Hulscher M, De Cock D, et al. An exploration of the relative importance of barriers hindering intensive combination treatment strategies in early rheumatoid arthritis. BMC Health Serv Res. 2014;14(Suppl 2):P147. doi: 10.1186/1472-6963-14-s2-p147. [CrossRef]

Mukherjee K, Kamal KM. Socio-demographic factors and out-of-pocket expenditure for prescription drugs in rheumatoid arthritis. Value Health. 2016;19(3):A232.

Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011 Dec 01;84(11):1245–52. PMID: 22150658. [PubMed: 22150658]

Ruffing V, Bingham, C. O., III. Rheumatoid Arthritis Signs and Symptoms. Johns Hopkins Arthritis Center; 2017. https://www​.hopkinsarthritis​.org/arthritis-info​/rheumatoid-arthritis​/ra-symptoms/#epi. Accessed on April 27 2017.

Centers for Disease Control and Prevention. Rheumatoid Arthritis Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2017. https://www​.cdc.gov/arthritis​/basics/rheumatoid-arthritis​.html. Accessed on April 12 2017.

Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996 May;39(5):732–5. PMID: 8639169. [PubMed: 8639169]

Millar K, Lloyd SM, McLean JS, et al. Personality, socio-economic status and inflammation: cross-sectional, population-based study. PLoS One. 2013;8(3):e58256. doi: 10.1371/journal.pone.0058256. PMID: 23516457. [PMC free article: PMC3596406] [PubMed: 23516457] [CrossRef]

Ebringer A, Wilson C. HLA molecules, bacteria and autoimmunity. J Med Microbiol. 2000 Apr;49(4):305–11. doi: 10.1099/0022-1317-49-4-305. PMID: 10755623. [PubMed: 10755623] [CrossRef]

Scher JU, Ubeda C, Equinda M, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012 Oct;64(10):3083–94. doi: 10.1002/art.34539. PMID: 22576262. [PMC free article: PMC3428472] [PubMed: 22576262] [CrossRef]

Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759–95. doi: 10.1146/annurev-immunol-020711-074937. PMID: 22224764. [PMC free article: PMC4426968] [PubMed: 22224764] [CrossRef]

MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000 Jan;43(1):30–7. doi: 10.1002/1529-0131(200001)43:1<30::aid-anr5>3.0.co;2-b. PMID: 10643697. [PubMed: 10643697] [CrossRef]

Holmdahl R. Association of MHC and rheumatoid arthritis: Why is rheumatoid arthritis associated with the MHC genetic region? An introduction. Arthritis Res. 2000;2(3):203–4. doi: 10.1186/ar87. PMID: PMC130002. [PMC free article: PMC130002] [PubMed: 11094429] [CrossRef]

Klein K, Gay S. Epigenetics in rheumatoid arthritis. Curr Opin Rheumatol. 2015 Jan;27(1):76–82. doi: 10.1097/bor.0000000000000128. PMID: 25415526. [PubMed: 25415526] [CrossRef]

Allaire S, Wolfe F, Niu J, et al. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum. 2009 Mar 15;61(3):321–8. doi: 10.1002/art.24281. PMID: 19248135. [PMC free article: PMC2758245] [PubMed: 19248135] [CrossRef]

Friedewald VE, Ganz P, Kremer JM, et al. AJC editor’s consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease. Am J Cardiol. 2010 Aug 01;106(3):442–7. doi: 10.1016/j.amjcard.2010.04.005. PMID: 20643261. [PubMed: 20643261] [CrossRef]

National Institute for Health and Health Care Excellence (NICE). Rheumatoid Arthritis in adults: management. [Practice Guideline]. London: National Institute for Health and Health Care Excellence; 2015. https://www​.nice.org​.uk/guidance/cg79/evidence. Accessed on February 2 2018.

Nam JL. Rheumatoid arthritis management of early disease. Curr Opin Rheumatol. 2016 May;28(3):267–74. doi: 10.1097/bor.0000000000000276. PMID: 26978129. [PubMed: 26978129] [CrossRef]

Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014, January. Chapters available at: www​.effectivehealthcare.ahrq.gov.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):21. [PMC free article: PMC3090117] [PubMed: 21603045]

Scott IC, Ibrahim F, Simpson G, et al. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):88–93. PMID: 26842950. [PubMed: 26842950]

Wallace BC, Small K, Brodley CE, et al. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium; 2012 Miami, Florida, USA. ACM; pp. 819–24.

U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Silver Spring, MD; 2017. https://www​.accessdata​.fda.gov/scripts/cdrh​/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32. Accessed on September 7, 2017. Last updated on August 14, 2017.

Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354. [PMC free article: PMC5062054] [PubMed: 27733354] [CrossRef]

Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011.

Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. AHRQ Publication No. 12-EHC047-EF. Rockville, MD: Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews; March 2012. www​.effectivehealthcare.ahrq.gov/.

White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012 Jun;3(2):111–25. doi: 10.1002/jrsm.1045. PMID: 26062085. [PMC free article: PMC4433771] [PubMed: 26062085] [CrossRef]

White IR. Network meta-analysis. Stata Journal. 2015;15(4):951–85.

Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2014 Dec 20;68(11):1312–24. doi: 10.1016/j.jclinepi.2014.11.023. PMID: 25721570. [PubMed: 25721570] [CrossRef]

Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018 Jan;93:36–44. doi: 10.1016/j.jclinepi.2017.10.005. PMID: 29051107. [PubMed: 29051107] [CrossRef]

Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011 Nov;64(11):1198–207. doi: 10.1016/j.jclinepi.2010.11.021. PMID: 21463926. [PubMed: 21463926] [CrossRef]

Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 2017 Apr;69(4):700–8. doi: 10.1002/art.40017. PMID: 27992692. [PubMed: 27992692] [CrossRef]

Bliddal H, Eriksen SA, Christensen R, et al. Adherence to methotrexate in rheumatoid arthritis: a Danish nationwide cohort study. Arthritis. 2015;2015. doi: 10.1155/2015/915142. [PMC free article: PMC4355606] [PubMed: 25810923] [CrossRef]

Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360–70. [PubMed: 16255010]

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005 Nov;52(11):3381–90. PMID: 16258899. [PubMed: 16258899]

Dirven L, van den Broek M, van Groenendael JH, et al. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskelet Disord. 2012 Jul 23;13:125. doi: 10.1186/1471-2474-13-125. PMID: 22824097. [PMC free article: PMC3485122] [PubMed: 22824097] [CrossRef]

Klarenbeek N, Kooij S, Huizinga T, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010;69(7):1342–5. doi: 10.1136/ard.2009.124180. PMID: CN-00748402. [PubMed: 20472597] [CrossRef]

Dirven L, Klarenbeek NB, van den Broek M, et al. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin Rheumatol. 2013 May;32(5):585–90. doi: 10.1007/s10067-012-2136-8. PMID: 23224330. [PubMed: 23224330] [CrossRef]

van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009 Jan 15;61(1):4–12. PMID: 19116965. [PubMed: 19116965]

Van Der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2008;67(2):266–9. PMID: 2008057728. [PubMed: 17947301]

Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406–15. PMID: 2008225574. [PubMed: 17371885]

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009 Jun;68(6):914–21. PMID: 18662933. [PubMed: 18662933]

Markusse IM, Akdemir G, Dirven L, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016 Apr 19;164(8):523–31. doi: 10.7326/m15-0919. PMID: 27089068. [PubMed: 27089068] [CrossRef]

Markusse IM, de Vries-Bouwstra JK, Han KH, et al. Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Res Ther. 2014 Sep 25;16(5):430. doi: 10.1186/s13075-014-0430-3. PMID: 25253199. [PMC free article: PMC4203912] [PubMed: 25253199] [CrossRef]

Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011 Jun;70(6):1039–46. doi: 10.1136/ard.2010.141234. PMID: 21415052. [PubMed: 21415052] [CrossRef]

Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011 Feb;70(2):315–9. doi: 10.1136/ard.2010.136556. PMID: 21068104. [PubMed: 21068104] [CrossRef]

Allaart C, Goekoop-Ruiterman Y, Vries-Bouwstra J, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol. 2012;24(6 Suppl 43):S-77-82. PMID: CN-00576834. [PubMed: 17083767]

Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009 Nov;48(11):1429–34. PMID: 19741011. [PubMed: 19741011]

Choy EH, Smith CM, Farewell V, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis; 2008. p. 656–63. [PubMed: 17768173]

Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012 Mar 06;156(5):329–39. doi: 10.7326/0003-4819-156-5-201203060-00004. PMID: 22393128. [PubMed: 22393128] [CrossRef]

Verschueren P, De Cock D, Corluy L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015 Apr 09;17:97. doi: 10.1186/s13075-015-0611-8. PMID: 25889222. [PMC free article: PMC4422551] [PubMed: 25889222] [CrossRef]

Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014 Jan;73(1):75–85. doi: 10.1136/annrheumdis-2013-203440. PMID: 23912798. [PubMed: 23912798] [CrossRef]

Hafstrem I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to diseasemodifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: An open 2-year continuation study. 2009. [PubMed: 18420939]

Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015 Jan;74(1):27–34. doi: 10.1136/annrheumdis-2014-205489. PMID: 25359382. [PubMed: 25359382] [CrossRef]

Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017;76(3):511–20. doi: 10.1136/annrheumdis-2016-209212. [PubMed: 27432356] [CrossRef]

Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002 Feb;46(2):347–56. PMID: 11840436. [PubMed: 11840436]

Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the Fin-Raco Study. Arthritis Rheum. 2004;50(7):2072–81. [PubMed: 15248204]

Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 2004;50(1):55–62. [PubMed: 14730599]

Kimel M, Cifaldi M, Chen N, et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol; 2008. p. 206–15. [PubMed: 18085743]

Maillefert JF, Combe B, Goupille P, et al. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis. 2003;62(8):764–6. [PMC free article: PMC1754629] [PubMed: 12860733]

ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. 2015 Jun;74(6):1233–40. doi: 10.1136/annrheumdis-2013-205143. PMID: 24818633. [PubMed: 24818633] [CrossRef]

Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009 Jun;68(6):823–7. PMID: 18593759. [PubMed: 18593759]

Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):716–22. PMID: 16508932. [PubMed: 16508932]

Emery P, Breedveld F, Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. In Arthritis Rheum [PubMed: 20187135]

Kekow J, Moots R, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. In Ann Rheum Dis [PubMed: 19293160]

Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–50. PMID: 12115173. [PubMed: 12115173]

Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006 Feb;33(2):234–43. PMID: 16465653. [PubMed: 16465653]

Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005 Jul;32(7):1232–42. PMID: 15996057. [PubMed: 15996057]

Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006 Dec;84(6):1463–72. PMID: 17158431. [PubMed: 17158431]

van Vollenhoven RF, Cifaldi MA, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010/03/02 ed; 2010. p. 226–34. [PubMed: 20191522]

van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol. 2010 Nov;37(11):2237–46. doi: 10.3899/jrheum.100208. PMID: 20889601. [PubMed: 20889601] [CrossRef]

Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012 Jan;39(1):63–72. doi: 10.3899/jrheum.101161. PMID: 22045836. [PubMed: 22045836] [CrossRef]

Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013 Jul;72(7):1156–62. doi: 10.1136/annrheumdis-2012-201620. PMID: 22915617. [PMC free article: PMC3686261] [PubMed: 22915617] [CrossRef]

Keystone EC, Breedveld FC, van der Heijde D, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan;41(1):5–14. doi: 10.3899/jrheum.130543. PMID: 24241487. [PubMed: 24241487] [CrossRef]

Landewe R, Smolen JS, Florentinus S, et al. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther. 2015 May 21;17:133. doi: 10.1186/s13075-015-0626-1. PMID: 25994819. [PMC free article: PMC4440309] [PubMed: 25994819] [CrossRef]

Heimans L, Akdemir G, Boer KV, et al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res Ther. 2016 Jan 21;18:23. doi: 10.1186/s13075-015-0912-y. PMID: 26794605. [PMC free article: PMC4721018] [PubMed: 26794605] [CrossRef]

Eriksson JK, Neovius M, Bratt J, et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med. 2013 Aug 12;173(15):1407–14. doi: 10.1001/jamainternmed.2013.7801. PMID: 23817631. [PubMed: 23817631] [CrossRef]

van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012 May 05;379(9827):1712–20. doi: 10.1016/s0140-6736(12)60027-0. PMID: 22464340. [PubMed: 22464340] [CrossRef]

Rezaei H, Saevarsdottir S, Geborek P, et al. Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial. In BMC Musculoskelet Disord [PMC free article: PMC3599105] [PubMed: 23497111]

Eriksson JK, Wallman JK, Miller H, et al. Infliximab versus conventional combination treatment and seven-year work loss in early rheumatoid arthritis: results of a randomized Swedish trial. Arthritis Care Res. 2016;68(12):1758–66. doi: 10.1002/acr.22899. [PMC free article: PMC6767553] [PubMed: 27015295] [CrossRef]

Levitsky A, Forslind K, van Vollenhoven RF. Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial. Scand J Rheumatol. 2015;44(5):348–53. doi: 10.3109/03009742.2015.1019560. PMID: 25992914. [PubMed: 25992914] [CrossRef]

Karlsson JA, Neovius M, Nilsson JA, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann Rheum Dis. 2013 Dec;72(12):1927–33. doi: 10.1136/annrheumdis-2012-202062. PMID: 23196701. [PubMed: 23196701] [CrossRef]

Kuusalo L, Puolakka K, Kautiainen H, et al. Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scand J Rheumatol. 2015;44(6):449–55. doi: 10.3109/03009742.2015.1043142. PMID: 26324784. [PubMed: 26324784] [CrossRef]

Rantalaiho V, Kautiainen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2014 Nov;73(11):1954–61. doi: 10.1136/annrheumdis-2013-203497. PMID: 23908187. [PubMed: 23908187] [CrossRef]

Wells AF, Westhovens R, Reed DM, et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011 Nov;38(11):2362–8. doi: 10.3899/jrheum.110054. PMID: 21885491. [PubMed: 21885491] [CrossRef]

Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011 Nov;70(11):1949–56. doi: 10.1136/ard.2010.145268. PMID: 21821865. [PubMed: 21821865] [CrossRef]

Smolen JS, Wollenhaupt J, Gomez-Reino JJ, et al. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther. 2015 Jun 11;17:157. doi: 10.1186/s13075-015-0671-9. PMID: 26063454. [PMC free article: PMC4494702] [PubMed: 26063454] [CrossRef]

Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar;71(3):351–7. doi: 10.1136/annrheumdis-2011-200170. PMID: 22012969. [PMC free article: PMC3277723] [PubMed: 22012969] [CrossRef]

Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011 May;63(5):711–20. doi: 10.1002/acr.20419. PMID: 21557525. [PubMed: 21557525] [CrossRef]

Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul;76(7):1279–84. doi: 10.1136/annrheumdis-2016-210561. PMID: 28389552. [PMC free article: PMC5530348] [PubMed: 28389552] [CrossRef]

Teitsma XM, Jacobs JWG, Welsing PMJ, et al. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. Rheumatology (Oxford). 2017 Dec 1;56(12):2179–89. doi: 10.1093/rheumatology/kex319. PMID: 29029185. [PubMed: 29029185] [CrossRef]

Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis. 2013 Jun;72(6):875–80. doi: 10.1136/annrheumdis-2012-201517. PMID: 22798565. [PubMed: 22798565] [CrossRef]

McWilliams DF, Kiely PD, Young A, et al. Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. BMC Musculoskelet Disord. 2013 May 01;14:153. doi: 10.1186/1471-2474-14-153. PMID: 23634781. [PMC free article: PMC3648486] [PubMed: 23634781] [CrossRef]

Hafstrom I, Engvall IL, Ronnelid J, et al. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. BMJ Open. 2014 Jul 30;4(7):e005246. doi: 10.1136/bmjopen-2014-005246. PMID: 25079933. [PMC free article: PMC4120364] [PubMed: 25079933] [CrossRef]

Svensson B, Andersson M, Forslind K, et al. Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study. Scand J Rheumatol. 2016 Nov;45(6):448–55. doi: 10.3109/03009742.2016.1147595. PMID: 27095008. [PubMed: 27095008] [CrossRef]

Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014 Apr 07;4(4):e004259. doi: 10.1136/bmjopen-2013-004259. PMID: 24710131. [PMC free article: PMC3987742] [PubMed: 24710131] [CrossRef]

Tuyl L, Boers M, Lems W, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):807–12. doi: 10.1136/ard.2009.108027. PMID: CN-00749418. [PubMed: 19451137] [CrossRef]

Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. In Arthritis Res Ther [PMC free article: PMC2911916] [PubMed: 20576092]

Rantalaiho V, Kautiainen H, Korpela M, et al. Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial. In Ann Rheum Dis [PubMed: 23349132]

Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol. 2007 Feb;34(2):316–21. PMID: 17183623. [PubMed: 17183623]

Karstila K, Rantalaiho V, Mustonen J, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. In Clin Exp Rheumatol [PubMed: 20346242]

de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014 Jul;73(7):1331–9. doi: 10.1136/annrheumdis-2013-204788. PMID: 24788619. [PMC free article: PMC4078755] [PubMed: 24788619] [CrossRef]

Kuijper TM, Luime JJ, De Jong PHP, et al. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Ann Rheum Dis. 2016;75(12):2119–23. doi: 10.1136/annrheumdis-2016-209272. [PubMed: 27283332] [CrossRef]

de Jong PH, Hazes JM, Buisman LR, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford). 2016 Dec;55(12):2138–47. doi: 10.1093/rheumatology/kew321. PMID: 27581208. [PubMed: 27581208] [CrossRef]

Vollenhoven R, Cifaldi M, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62(2):226–34. doi: 10.1002/acr.20072. PMID: CN-00734281. [PubMed: 20191522] [CrossRef]

Yamanaka H, Ishiguro N, Takeuchi T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014 May;53(5):904–13. doi: 10.1093/rheumatology/ket465. PMID: 24441150. [PMC free article: PMC3988871] [PubMed: 24441150] [CrossRef]

Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014 Jan 25;383(9914):321–32. doi: 10.1016/s0140-6736(13)61751-1. PMID: 24168956. [PubMed: 24168956] [CrossRef]

Emery P, Smolen JS, Ganguli A, et al. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (United Kingdom). 2016;55(8):1458–65. doi: 10.1093/rheumatology/kew056. [PubMed: 27114561] [CrossRef]

Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017 Aug;76(8):1348–56. doi: 10.1136/annrheumdis-2016-210246. PMID: 28153828. [PMC free article: PMC5738604] [PubMed: 28153828] [CrossRef]

Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford); 2009. p. 1283–9. [PubMed: 19690125]

Zhang W, Sun H, Emery P, et al. Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis? Rheumatology (Oxford). 2012 Feb;51(2):270–4. doi: 10.1093/rheumatology/ker189. PMID: 21719418. [PubMed: 21719418] [CrossRef]

Dougados MR, van der Heijde DM, Brault Y, et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). J Rheumatol. 2014 Oct;41(10):1922–34. doi: 10.3899/jrheum.131238. PMID: 25128520. [PubMed: 25128520] [CrossRef]

Janssen Research and Development LLC. Janssen Response to Data Requested by the Agency for Healthcare Research and Quality on Drug Therapy for Early Rheumatoid Arthritis in Adults – An Update. 2017. p. 1–11.

Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2014 Jul;73(7):1356–61. doi: 10.1136/annrheumdis-2013-203243. PMID: 23716067. [PubMed: 23716067] [CrossRef]

O’Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013 Aug;65(8):1985–94. doi: 10.1002/art.38012. PMID: 23686414. [PMC free article: PMC4768726] [PubMed: 23686414] [CrossRef]

Ammitzboll CG, Thiel S, Jensenius JC, et al. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. Arthritis Rheum. 2013 Dec;65(12):3045–50. doi: 10.1002/art.38179. PMID: 24022747. [PubMed: 24022747] [CrossRef]

Axelsen MB, Eshed I, Horslev-Petersen K, et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis. 2015 May;74(5):867–75. doi: 10.1136/annrheumdis-2013-204537. PMID: 24412895. [PubMed: 24412895] [CrossRef]

Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, et al. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Ann Rheum Dis. 2016;75(9):1645–53. doi: 10.1136/annrheumdis-2015-208166. [PubMed: 26489704] [CrossRef]

Ørnbjerg LM, Østergaard M, Jensen T, et al. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clin Rheumatol. 2017;36(4):781–9. doi: 10.1007/s10067-016-3489-1. [PubMed: 27921185] [CrossRef]

van Vollenhoven RF, Cifaldi MA, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res. 62:226. [PubMed: 20191522]

Orbai AM, Bingham CO, 3rd. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015 Apr;17(4):28. doi: 10.1007/s11926-015-0501-8. PMID: 25854489. [PMC free article: PMC4404708] [PubMed: 25854489] [CrossRef]

Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000 Jul;43(7):1478–87. doi: 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M. PMID: 10902749. [PubMed: 10902749] [CrossRef]

Busija L, Pausenberger E, Haines TP, et al. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S383–412. doi: 10.1002/acr.20541. PMID: 22588759. [PubMed: 22588759] [CrossRef]

Levitsky A, Brismar K, Hafström I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: Results from the SWEFOT trial. RMD Open. 2017;3(2). doi: 10.1136/rmdopen-2017-000458. [PMC free article: PMC5574420] [PubMed: 28879052] [CrossRef]

van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34(Suppl 2):74–8. PMID: 8535653. [PubMed: 8535653]

Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017 Oct;9(10):249–62. doi: 10.1177/1759720x17720366. PMID: 28974987. [PMC free article: PMC5613855] [PubMed: 28974987] [CrossRef]

Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep. 2012 Oct;14(5):472–80. doi: 10.1007/s11926-012-0275-1. PMID: 22773387. [PMC free article: PMC3616381] [PubMed: 22773387] [CrossRef]

Prince FH, Bykerk VP, Shadick NA, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther. 2012 Mar 19;14(2):R68. doi: 10.1186/ar3785. PMID: 22429277. [PMC free article: PMC3446437] [PubMed: 22429277] [CrossRef]

Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000 Jan;43(1):22–9. doi: 10.1002/1529-0131(200001)43:1<22::aid-anr4>3.0.co;2-9. PMID: 10643696. [PubMed: 10643696] [CrossRef]

Tymms K, Zochling J, Scott J, et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res (Hoboken). 2014 Feb;66(2):190–6. doi: 10.1002/acr.22108. PMID: 23983001. [PubMed: 23983001] [CrossRef]

Bonafede M, Johnson BH, Fox KM, et al. Risk factors for non-initiation of disease modifyinganti-rheumatic drugs (DMARD) by patients with newlydiagnosed rheumatoid arthritis (RA). Value Health. 2011;14(3):A123.

Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001 Sep;60(9):817–27. PMID: 11502606. [PMC free article: PMC1753828] [PubMed: 11502606]

Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985 Dec;28(12):1326–35. PMID: 4084327. [PubMed: 4084327]

van der Heijde D, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford). 1999 Oct;38(10):941–7. PMID: 10534543. [PubMed: 10534543]

van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999 Mar;26(3):743–5. PMID: 10090194. [PubMed: 10090194]

Ory PA. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis. 2003 Jul;62(7):597–604. PMID: 12810418. [PMC free article: PMC1754596] [PubMed: 12810418]

Larsen A. Radiological grading of rheumatoid arthritis. An interobserver study. Scand J Rheumatol. 1973;2(3):136–8. PMID: 4769066. [PubMed: 4769066]

Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh). 1977 Jul;18(4):481–91. PMID: 920239. [PubMed: 920239]

Scott DL, Coulton BL, Bacon PA, et al. Methods of X-ray assessment in rheumatoid arthritis: a re-evaluation. Br J Rheumatol. 1985 Feb;24(1):31–9. PMID: 3978364. [PubMed: 3978364]

Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol. 1995;22:1974–5. [PubMed: 8992003]

Edmonds J, Saudan A, Lassere M, et al. Introduction to reading radiographs by the Scott modification of the Larsen method. J Rheumatol. 1999;26:740–2. [PubMed: 10090193]

Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 Feb;23(2):137–45. PMID: 7362664. [PubMed: 7362664]

Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 -- Status and Review. In: Spilker B, ed Quality of Life and Pharmacoleconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Publischers; 1996:227–37.

Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988 Jul;26(7):724–35. PMID: 3393032. [PubMed: 3393032]

Stewart AL, Ware JE. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.

Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–83. PMID: 1593914. [PubMed: 1593914]

McHorney CA, Ware JE, Jr., Rogers W, et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992 May;30(5 Suppl):MS253–65. PMID: 1583937. [PubMed: 1583937]

McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993 Mar;31(3):247–63. PMID: 8450681. [PubMed: 8450681]

McHorney CA, Ware JE, Jr., Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994 Jan;32(1):40–66. PMID: 8277801. [PubMed: 8277801]

Ware JE, Jr., Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995 Apr;33(4 Suppl):AS264–79. PMID: 7723455. [PubMed: 7723455]

Kind P. The EuroQol instrument: An index of health-related quality of life. Quality of life and PharmacoEconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996.

Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997 May;36(5):551–9. PMID: 9189057. [PubMed: 9189057]

Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–40. PMID: 8507213. [PubMed: 8507213]

Felson DT, Anderson JJ, Boers M, et al. ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35. [PubMed: 7779114]

van Gestel AM, Prevoo ML, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996 Jan;39(1):34–40. PMID: 8546736. [PubMed: 8546736]

Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009/12/08 ed; 2009. p. 745–57, vii–viii. [PubMed: 19962619]

van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol. 1999/03/25 ed; 1999. p. 705–11. [PubMed: 10090187]

Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806. PMID: 15987481. [PMC free article: PMC1175030] [PubMed: 15987481]

Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. PMID: 4877784. [PubMed: 4877784]

Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–81. doi: 10.1002/art.27584. PMID: 20872595. [PubMed: 20872595] [CrossRef]